Schedule 13G ownership disclosure
NLS PHARMACEUTICS LTD
Security class unavailable · CUSIP: H57830103
Event date: 2024-03-22
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 9.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-24-001262
- Form type
- SC 13G
- Filer
- Lind Global Fund II LP
- CIK
- CIK 1871665
- Filed
- Mar 27, 2024
- Reporting period
- Mar 22, 2024
- Description
- Schedule 13G beneficial ownership